Pembrolizumab in relapsed or refractory Richter syndrome-Reference-Cited by-同舟云学术

Pembrolizumab in relapsed or refractory Richter syndrome

Published:2020-06-16 Issue:2 Volume:190 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Armand Philippe¹^ORCID,Murawski Niels²,Molin Daniel³,Zain Jasmine⁴,Eichhorst Barbara⁵,Gulbas Zafer⁶,Hawkes Eliza A.⁷^ORCID,Pagel John M.⁸,Phillips Tycel⁹^ORCID,Ribrag Vincent¹⁰^ORCID,Svoboda Jakub¹¹,Stathis Anastasios¹²,Chatterjee Arkendu¹³,Orlowski Robert¹³,Marinello Patricia¹³,Christian Beth¹⁴

Affiliation:

1. Dana‐Farber Cancer Institute Boston MA USA

2. Universitäts‐klinikum des Saarlandes Innere Medizin I Homburg Germany

3. Experimental and Clinical Oncology Department of ImmunologyGenetics and Pathology Uppsala University Uppsala Sweden

4. City of Hope Duarte CA USA

5. University of Cologne Cologne Germany

6. Anadolu Medical Center Istanbul Turkey

7. Olivia Newton‐John Cancer Research Institute Austin Health Victoria Australia

8. Swedish Center for Blood Disorders and Stem Cell Transplants Swedish Cancer Institute Seattle WAUSA

9. Rogel Cancer Center Ann Arbor MI USA

10. Institut Gustave Roussy Villejuif France

11. Perelman Center for Advanced Medicine University of Pennsylvania Philadelphia PA USA

12. Oncology Institute of Southern Switzerland Bellinzona Switzerland

13. Merck & Co., Inc Kenilworth NJUSA

14. The James Cancer Hospital and Solove Research Institute Ohio State University Columbus OH USA

Funder

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16762

Reference14 articles.

Immunochemotherapy for Richter syndrome: current insights

2. Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison tode novoHodgkin lymphoma

3. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients

4. Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation

5. Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia;Leukemia & Lymphoma;2024-09-02

2. Targeting chronic lymphocytic leukemia with B‐cell activating factor receptor CAR T cells;MedComm;2024-09

3. Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial;The Lancet Oncology;2024-09

4. SOHO State of the Art Updates and Next Questions | Contemporary Standard of Care Therapy for Richter's Transformation and Future Directions;Clinical Lymphoma Myeloma and Leukemia;2024-07

5. Are we closer to a standard of care for Richter’s syndrome? Novel treatments on the horizon;Expert Review of Hematology;2024-05-03